BACKGROUND: The previous OLIVUS trial reported a positive role in achieving a lower rate
of coronary atheroma progression through the administration of Olmesartan, an …

Objectives: The aim of this study was to evaluate the impact of olmesartan on progression of
coronary atherosclerosis. Background: Prior intravascular ultrasound (IVUS) trial results …

Cardiovascular (CV) disease is a major factor in mortality rates around the world and
contributes to more than one-third of deaths in the US. The underlying cause of CV disease …

ASTEROID is a prospective, open-label blinded end-points trial aiming to assess whether
very intensive statin therapy with rosuvastatin 40 mg/day could regress coronary …

Background—Activation of the renin-angiotensin-aldosterone system and oxidative
modification of LDL cholesterol play important roles in atherosclerosis. The Study to …

Olmesartan medoxomil is an angiotensin II receptor antagonist. In pooled analyses of seven
randomized, double-blind trials, 8 weeks' treatment with olmesartan medoxomil was …

BACKGROUND: In patients with coronary artery disease (CAD), therapies designed to
prevent clinical events are not always associated with significant reduction in coronary …

Background Although the positive association between achieved low-density lipoprotein
cholesterol (LDL-C) level and the risk of coronary artery disease (CAD) has been confirmed …

ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

Coronary plaques can be reduced by some medications. The aim of this study was to
compare the effects of 2 angiotensin II receptor blockers (olmesartan at 20 mg/day or …